Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 15.26
+0.84 (5.83%)
Aug 26, 2026, 3:04 PM CST
Walvax Biotechnology Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 970.1 | 1,353 | 3,764 | 4,365 | 3,873 | 3,443 |
Short-Term Investments | - | 311.84 | - | - | - | - |
Cash & Short-Term Investments | 970.1 | 1,665 | 3,764 | 4,365 | 3,873 | 3,443 |
Cash Growth | -72.32% | -55.77% | -13.77% | 12.68% | 12.49% | 75.54% |
Accounts Receivable | 2,288 | 2,145 | 2,410 | 3,101 | 3,577 | 2,481 |
Other Receivables | 80.59 | 74.42 | 58.8 | 114.18 | 416.13 | 774.86 |
Receivables | 2,369 | 2,220 | 2,468 | 3,215 | 3,993 | 3,255 |
Inventory | 561.74 | 574.16 | 752.59 | 1,035 | 995.81 | 873.59 |
Other Current Assets | 428.68 | 87.76 | 82.22 | 119.21 | 86.25 | 107.94 |
Total Current Assets | 4,329 | 4,546 | 7,067 | 8,733 | 8,948 | 7,680 |
Property, Plant & Equipment | 4,015 | 4,032 | 4,079 | 3,768 | 3,161 | 2,604 |
Long-Term Investments | 474 | 1,367 | 1,638 | 1,057 | 1,292 | 1,491 |
Goodwill | 33.66 | 33.66 | 33.66 | 33.66 | 33.66 | 33.66 |
Other Intangible Assets | 816.96 | 831.43 | 1,035 | 1,086 | 1,167 | 434.98 |
Long-Term Accounts Receivable | - | 3.67 | 7.27 | - | - | - |
Long-Term Deferred Tax Assets | 106.93 | 110.81 | 104.56 | 103.44 | 124.84 | 168.01 |
Long-Term Deferred Charges | 608.53 | 586.4 | 513.86 | 473.48 | 309.38 | 1,022 |
Other Long-Term Assets | 744.14 | 559.32 | 246.62 | 333.54 | 300.2 | 240.63 |
Total Assets | 11,128 | 12,071 | 14,724 | 15,589 | 15,336 | 13,674 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 1,296 | 1,368 | 1,568 | 1,805 | 1,836 | 1,258 |
Accrued Expenses | 37.81 | 212.79 | 549.81 | 722.05 | 1,145 | 754.71 |
Short-Term Debt | 375.59 | 163.43 | - | 320.27 | 97.18 | 310 |
Current Portion of Long-Term Debt | 57.3 | 7.66 | 38.98 | 8.79 | - | - |
Current Portion of Leases | - | 11.47 | 7.85 | 21.88 | 23.35 | 4.6 |
Current Income Taxes Payable | 23.38 | 2.71 | - | 14.13 | 19.47 | 2.03 |
Current Unearned Revenue | 15.96 | 20.42 | 106.18 | 160.47 | 192.96 | 35.29 |
Other Current Liabilities | 195.93 | 150.64 | 99.4 | 151.25 | 194.15 | 870.61 |
Total Current Liabilities | 2,002 | 1,937 | 2,370 | 3,204 | 3,509 | 3,235 |
Long-Term Debt | 917.26 | 189.56 | 433.34 | 434.9 | 314.24 | - |
Long-Term Leases | 12.82 | 16.52 | 11.77 | 20.6 | 27.74 | 1.06 |
Long-Term Unearned Revenue | 260.53 | 276.77 | 278.44 | 423.33 | 404.53 | 344.3 |
Long-Term Deferred Tax Liabilities | 16.24 | 16.42 | 55.91 | 68.71 | 90.94 | 94.56 |
Other Long-Term Liabilities | 106.06 | 97.8 | 67 | 42.08 | - | - |
Total Liabilities | 3,315 | 2,534 | 3,216 | 4,194 | 4,346 | 3,675 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 1,599 | 1,599 | 1,599 | 1,607 | 1,607 | 1,601 |
Additional Paid-In Capital | 2,090 | 3,414 | 4,549 | 4,900 | 4,965 | 4,772 |
Retained Earnings | 3,719 | 3,224 | 3,110 | 2,984 | 2,580 | 1,895 |
Treasury Stock | - | - | - | -358.63 | -286.42 | - |
Comprehensive Income & Other | - | 384.29 | 171.28 | 217.18 | 217.18 | 216.33 |
Total Common Equity | 7,408 | 8,621 | 9,430 | 9,349 | 9,084 | 8,484 |
Minority Interest | 404.99 | 915.4 | 2,078 | 2,046 | 1,906 | 1,515 |
Shareholders' Equity | 7,813 | 9,536 | 11,508 | 11,395 | 10,990 | 9,999 |
Total Liabilities & Equity | 11,128 | 12,071 | 14,724 | 15,589 | 15,336 | 13,674 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 1,363 | 388.63 | 491.94 | 806.42 | 462.51 | 315.67 |
Net Cash (Debt) | -392.87 | 1,276 | 3,272 | 3,558 | 3,411 | 3,128 |
Net Cash Growth | - | -61.00% | -8.05% | 4.31% | 9.06% | 62.77% |
Net Cash Per Share | -0.24 | 0.80 | 2.05 | 2.22 | 2.13 | 1.99 |
Filing Date Shares Outstanding | 1,599 | 1,599 | 1,599 | 1,599 | 1,601 | 1,601 |
Total Common Shares Outstanding | 1,599 | 1,599 | 1,599 | 1,599 | 1,601 | 1,601 |
Working Capital | 2,327 | 2,609 | 4,697 | 5,529 | 5,440 | 4,445 |
Book Value Per Share | 4.63 | 5.39 | 5.90 | 5.85 | 5.67 | 5.30 |
Tangible Book Value | 6,558 | 7,756 | 8,361 | 8,230 | 7,883 | 8,016 |
Tangible Book Value Per Share | 4.10 | 4.85 | 5.23 | 5.15 | 4.92 | 5.01 |
Buildings | - | 954.86 | 953.95 | 948.5 | 767.91 | 541.68 |
Machinery | - | 2,223 | 2,196 | 2,093 | 1,580 | 1,235 |
Construction In Progress | - | 2,284 | 2,114 | 1,645 | 1,509 | 1,527 |